-
Counting the dead in Gaza: difficult but essential Lancet (IF 98.4) Pub Date : 2024-07-05 Rasha Khatib, Martin McKee, Salim Yusuf
-
Physician associates in the UK and the role of the doctor Lancet (IF 98.4) Pub Date : 2024-07-04 Jessamy Bagenal
-
Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis Lancet (IF 98.4) Pub Date : 2024-06-28 I Sermet-Gaudelus, Sihem Benaboud, Stéphanie Bui, Tiphaine Bihouée, Sophie Gautier, MODUL-CF study group, Mahassen Barboura, Audrey Barzic, Lilia Benhalla, Khadidja Bennour, Katia Bessaci, Antoine Bessou, Thiphaine Bihouee, Anne-Sophie Bonnel, Nesrine Bouleghem, Stéphanie Bui, Frédérique Chedevergne, Harriet Corvol, Laure Cosson, Laure Couderc, Marie-Laure Dalphin, Paola De carli, Eric Deneuville,
-
Delivering the promise of improved health for women and girls in England Lancet (IF 98.4) Pub Date : 2024-06-27 Jane Elizabeth Hirst, Alice Witt, Edward Mullins, Kate Womersley, Dorcus Muchiri, Robyn Norton
-
Diabetes management amidst floods in Brazil Lancet (IF 98.4) Pub Date : 2024-06-26 Lucas Strassburger Matzenbacher, Janine Alessi, Gabriela Heiden Telo
-
Floods in south Brazil: more than an environmental crisis Lancet (IF 98.4) Pub Date : 2024-06-26 Guilherme Pinheiro Machado
-
Implications of suboptimal measles immunity in UK health-care workers Lancet (IF 98.4) Pub Date : 2024-06-26 Antonia Ho, Oliver Galgut, Sian Faustini, Nicholas Peters, Adrian Shields, Paul Klenerman, Susan Hopkins, Victoria Hall, Susanna Dunachie, Alex Richter
-
Oral diseases in Palestine Lancet (IF 98.4) Pub Date : 2024-06-25 David T Zhu, Kate Zinszer, Samer Abuzerr
-
-
Pathophysiology from preconception, during pregnancy, and beyond Lancet (IF 98.4) Pub Date : 2024-06-20 Marie-France Hivert MD, Helena Backman PhD, Katrien Benhalima PhD, Prof Patrick Catalano MD, Prof Gernot Desoye PhD, Jincy Immanuel PhD, Christopher J D McKinlay PhD, Prof Claire L Meek PhD, Prof Christopher J Nolan PhD, Uma Ram FRCOG, Arianne Sweeting PhD, Prof David Simmons MD CANTAB, Prof Alicia Jawerbaum PhD
Gestational diabetes is the most common medical complication in pregnancy. Historically, gestational diabetes was considered a pregnancy complication involving treatment of rising glycaemia late in the second trimester. However, recent evidence challenges this view. Pre-pregnancy and pregnancy-specific factors influence gestational glycaemia, with open questions regarding roles of non-glycaemic factors
-
Call to action for a life course approach Lancet (IF 98.4) Pub Date : 2024-06-20 Prof David Simmons MD [Cantab], Yashdeep Gupta DM, Prof Teri L Hernandez PhD, Prof Naomi Levitt MD, Prof Mireille van Poppel PhD, Prof Xilin Yang PhD, Prof Christina Zarowsky PhD, Helena Backman PhD, Maisa Feghali MD, Karoline Kragelund Nielsen PhD
Gestational diabetes remains the most common medical disorder in pregnancy, with short-term and long-term consequences for mothers and offspring. New insights into pathophysiology and management suggest that the current gestational diabetes treatment approach should expand from a focus on late gestational diabetes to a personalised, integrated life course approach from preconception to postpartum and
-
Epidemiology and management of gestational diabetes Lancet (IF 98.4) Pub Date : 2024-06-20 Arianne Sweeting PhD, Wesley Hannah PhD, Helena Backman PhD, Prof Patrick Catalano MD, Maisa Feghali MD, Prof Willliam H Herman MD, Marie-France Hivert MD, Jincy Immanuel PhD, Prof Claire Meek PhD, Maria Lucia Oppermann PhD, Prof Christopher J Nolan PhD, Uma Ram FRCOG, Prof Maria Inês Schmidt MD, Prof David Simmons MD, Tawanda Chivese PhD, Prof Katrien Benhalima PhD
Gestational diabetes is defined as hyperglycaemia first detected during pregnancy at glucose concentrations that are less than those of overt diabetes. Around 14% of pregnancies globally are affected by gestational diabetes; its prevalence varies with differences in risk factors and approaches to screening and diagnosis; and it is increasing in parallel with obesity and type 2 diabetes. Gestational
-
Physical activity to prevent recurrences of low back pain Lancet (IF 98.4) Pub Date : 2024-06-19 Diarmuid Denneny, Jackie Walumbe
-
Effectiveness and cost-effectiveness of an individualised, progressive walking and education intervention for the prevention of low back pain recurrence in Australia (WalkBack): a randomised controlled trial Lancet (IF 98.4) Pub Date : 2024-06-19 Natasha C Pocovi PhD, Prof Chung-Wei Christine Lin PhD, Prof Simon D French PhD, Petra L Graham PhD, Johanna M van Dongen PhD, Prof Jane Latimer PhD, Prof Dafna Merom PhD, Prof Anne Tiedemann PhD, Prof Christopher G Maher DMedSc, Ornella Clavisi MPH, Shuk Yin Kate Tong MRes, Prof Mark J Hancock PhD
Recurrence of low back pain is common and a substantial contributor to the disease and economic burden of low back pain. Exercise is recommended to prevent recurrence, but the effectiveness and cost-effectiveness of an accessible and low-cost intervention, such as walking, is yet to be established. We aimed to investigate the clinical effectiveness and cost-effectiveness of an individualised, progressive
-
Political courage needed to prevent the next pandemic Lancet (IF 98.4) Pub Date : 2024-06-18 Helen Clark, Mauricio Cárdenas, Mark Dybul, Michel Kazatchkine, Joanne Liu, Henry E Mark, Rosemary McCarney, Christine McNab, David Miliband, Anders Nordström, Thoraya Ahmed Obaid, Raj Panjabi, Elizabeth Radin, George Werner, Ellen Johnson Sirleaf
-
The updated International Health Regulations: good news for global health equity Lancet (IF 98.4) Pub Date : 2024-06-17 Ashley Bloomfield, Abdullah Assiri
-
Peptic ulcer disease Lancet (IF 98.4) Pub Date : 2024-06-14 Majid A Almadi MBBS MSc, Yidan Lu MDCM, Ali A Alali MBBCh BAO MSc, Alan N Barkun MDCM MSc
Annual prevalence estimates of peptic ulcer disease range between 0·12% and 1·5%. Peptic ulcer disease is usually attributable to infection, intake of some medications (such as aspirin and non-steroidal anti-inflammatory medications), or being critically ill (stress-related), or it can be idiopathic. The clinical presentation is usually uncomplicated, with peptic ulcer disease management based on eradicating
-
Protecting the blood donor: ferritin-based intervals to improve donor health Lancet (IF 98.4) Pub Date : 2024-06-13 Laura Infanti
-
Effectiveness of ferritin-guided donation intervals in whole-blood donors in the Netherlands (FIND'EM): a stepped-wedge cluster-randomised trial Lancet (IF 98.4) Pub Date : 2024-06-13 Amber Meulenbeld MSc, Steven Ramondt PhD, Maike G Sweegers PhD, Franke A Quee MSc, Femmeke J Prinsze PhD, Emiel O Hoogendijk PhD, Prof Dorine W Swinkels PhD, Katja van den Hurk PhD
Whole-blood donors are at increased risk for iron deficiency and anaemia. The current standard of haemoglobin monitoring is insufficient to ensure the maintenance of proper iron reserves and donor health. We aimed to determine the effects of ferritin-guided donation intervals for blood donor health and blood supply in the Netherlands. In this stepped-wedge cluster-randomised trial (FIND'EM), the 138
-
A programme for greater health equity for the next UK Government Lancet (IF 98.4) Pub Date : 2024-06-13 Michael Marmot, Jessica Allen
-
Neoadjuvant therapy for oesophageal cancer: refining the armamentarium Lancet (IF 98.4) Pub Date : 2024-06-11 Salah-Eddin Al-Batran, Christine Koch
-
Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration Lancet (IF 98.4) Pub Date : 2024-06-11 Gui-shuang Ying, Brian L VanderBeek
-
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial Lancet (IF 98.4) Pub Date : 2024-06-11 Ken Kato MD PhD, Ryunosuke Machida ME, Yoshinori Ito MD PhD, Hiroyuki Daiko MD, Soji Ozawa MD PhD, Takashi Ogata MD PhD, Hiroki Hara MD, Takashi Kojima MD, Tetsuya Abe MD, Takeo Bamba MD, Masaya Watanabe MD, Hirofumi Kawakubo MD PhD, Yuichi Shibuya MD, Yasuhiro Tsubosa MD, Naoki Takegawa MD PhD, Takeshi Kajiwara MD PhD, Hideo Baba MD PhD, Masaki Ueno MD PhD, Hiroya Takeuchi MD PhD, Kenichi Nakamura
Neoadjuvant therapy is the standard treatment for patients with locally advanced oesophageal squamous cell carcinoma (OSCC). However, the prognosis remains poor and more intensive neoadjuvant treatment might be needed to improve patient outcomes. We therefore aimed to compare the efficacy and safety of neoadjuvant doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy plus radiotherapy
-
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial Lancet (IF 98.4) Pub Date : 2024-06-11 Prof Timothy L Jackson FRCOphth, Riti Desai MPhil, Hatem A Wafa MPH, Prof Yanzhong Wang PhD, Prof Janet Peacock PhD, Prof Tunde Peto PhD, Prof Usha Chakravarthy FRCOphth, Helen Dakin DPhil, Prof Sarah Wordsworth PhD, Cornelius Lewis MSc, Patricia Clinch MSc, Lisa Ramazzotto MPharm, James E Neffendorf FRCOphth, Chan Ning Lee FRCOphth, Prof Joe M O'Sullivan PhD, Prof Barnaby C Reeves DPhil, STAR study
Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness. The first-line therapy is anti-vascular endothelial growth factor (anti-VEGF) agents delivered by intravitreal injection. Ionising radiation mitigates key pathogenic processes underlying nAMD, and therefore has therapeutic potential. STAR aimed to assess whether stereotactic radiotherapy (SRT) reduces the number of
-
Colchicine for the prevention of vascular events after non-cardioembolic stroke Lancet (IF 98.4) Pub Date : 2024-06-07 Aristeidis H Katsanos, Ashkan Shoamanesh
-
Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial Lancet (IF 98.4) Pub Date : 2024-06-07 Prof Peter Kelly MD, Prof Robin Lemmens MD, Prof Christian Weimar MD, Prof Cathal Walsh PhD, Prof Francisco Purroy MD, Prof Mark Barber MD, Ronan Collins MD, Prof Simon Cronin PhD, Prof Anna Czlonkowska MD, Philippe Desfontaines MD, Adinda De Pauw MD, Nicholas Richard Evans PhD, Prof Urs Fischer MD, Catarina Fonseca MD, Prof John Forbes PhD, Prof Michael D Hill MD, Prof Dalius Jatuzis PhD, Prof Janika
Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent
-
Optimising treatment for chronic subdural haematoma Lancet (IF 98.4) Pub Date : 2024-06-06 Keita Shibahashi
-
Burr-hole drainage with or without irrigation for chronic subdural haematoma (FINISH): a Finnish, nationwide, parallel-group, multicentre, randomised, controlled, non-inferiority trial Lancet (IF 98.4) Pub Date : 2024-06-06 Rahul Raj MD PhD, Pihla Tommiska MD PhD, Timo Koivisto MD PhD, Prof Ville Leinonen MD PhD, Nils Danner MD PhD, Jussi P Posti MD PhD, Dan Laukka MD PhD, Teemu Luoto MD PhD, Minna Rauhala MD PhD, Sami Tetri MD PhD, Tommi K Korhonen MD PhD, Jarno Satopää MD PhD, Riku Kivisaari MD PhD, Teemu Luostarinen MD PhD, Christoph Schwartz MD MHBA, Tomasz Czuba MSc, Simo Taimela MD PhD, Kimmo Lönnrot MD PhD, Prof
Chronic subdural haematoma is a common surgically treated intracranial emergency. Burr-hole drainage surgery, to evacuate chronic subdural haematoma, involves three elements: creation of a burr hole for access, irrigation of the subdural space, and insertion of a subdural drain. Although the subdural drain has been established as beneficial, the therapeutic effect of subdural irrigation has not been
-
The developing role of theranostics in NETs Lancet (IF 98.4) Pub Date : 2024-06-05 Robert A Ramirez, Cathy Eng
-
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study Lancet (IF 98.4) Pub Date : 2024-06-05 Simron Singh MD, Daniel Halperin MD, Sten Myrehaug MD, Ken Herrmann MD, Prof Marianne Pavel MD, Pamela L Kunz MD, Beth Chasen MD, Salvatore Tafuto MD, Secondo Lastoria MD, Jaume Capdevila MD, Amparo García-Burillo MD, Do-Youn Oh MD, Changhoon Yoo MD, Thorvardur R Halfdanarson MD, Stephen Falk MD, Ilya Folitar MD, Yufen Zhang PhD, Paola Aimone MD, Wouter W de Herder MD, Diego Ferone MD, all the NETTER-2
There are currently no standard first-line treatment options for patients with higher grade 2–3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [Lu]Lu-DOTA-TATE (Lu-Dotatate) treatment. NETTER-2 was an open-label, randomised, parallel-group, superiority, phase 3 trial. We enrolled patients (aged ≥15 years)
-
Aftercare for surgically treated ankle fractures Lancet (IF 98.4) Pub Date : 2024-06-04 Tim Schepers, Jens A Halm
-
Early versus delayed weight-bearing following operatively treated ankle fracture (WAX): a non-inferiority, multicentre, randomised controlled trial Lancet (IF 98.4) Pub Date : 2024-06-04 Christopher Patrick Bretherton PhD, Juul Achten PhD, Vidoushee Jogarah MSc, Prof Stavros Petrou PhD, Nicholas Peckham MSc, Felix Achana PhD, Duncan Appelbe PhD, Prof Rebecca Kearney PhD, Harry Claireux MBChB, Philip Bell PhD, Prof Xavier L Griffin PhD, WAX Investigators, Andrew McAndrew, Neal Jacobs, Justin Forder, Thomas Hester, Charlotte Cross, Tony Bateman, Will Kieffer, Tristan Barton, Richard
After surgery for a broken ankle, patients are usually instructed to avoid walking for 6 weeks (delayed weight-bearing). Walking 2 weeks after surgery (early weight-bearing) might be a safe and preferable rehabilitation strategy. This study aimed to determine the clinical and cost effectiveness of an early weight-bearing strategy compared with a delayed weight-bearing strategy. This was a pragmatic
-
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet (IF 98.4) Pub Date : 2024-06-03 Prof Hans Gelderblom MD, Vivek Bhadri MD, Silvia Stacchiotti MD, Prof Sebastian Bauer MD, Andrew J Wagner MD, Prof Michiel van de Sande MD, Nicholas M Bernthal MD, Antonio López Pousa MD, Albiruni Abdul Razak BM BCh, Prof Antoine Italiano MD, Mahbubl Ahmed MD, Prof Axel Le Cesne MD, Gabriel Tinoco MD, Kjetil Boye MD, Javier Martín-Broto MD, Emanuela Palmerini MD, Salvatore Tafuto MD, Sarah Pratap DPhil
Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm for which few systemic treatment options exist. This study evaluated the efficacy and safety of vimseltinib, an oral, switch-control, CSF1R inhibitor, in patients with symptomatic TGCT not amenable to surgery. MOTION is a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial done in 35 specialised hospitals in
-
Vimseltinib for tenosynovial giant cell tumour Lancet (IF 98.4) Pub Date : 2024-06-03 Hiroshi Urakawa, Shiro Imagama
-
Calls for a focus on health risks in EU election Lancet (IF 98.4) Pub Date : 2024-05-30 Udani Samarasekera
-
Uproar over Women in Global Health leadership changes Lancet (IF 98.4) Pub Date : 2024-05-30 Udani Samarasekera
-
Offline: UK election—two issues you won’t hear about Lancet (IF 98.4) Pub Date : 2024-05-30 Richard Horton
-
-
-
-
-
The Lancet Group's new guidance to authors on reporting race and ethnicity Lancet (IF 98.4) Pub Date : 2024-05-30 Mabel Chew, Diana Samuel, The Lancet Group for Racial Equity (GRacE), Zoë Mullan, Sabine Kleinert
-
Primary adrenal insufficiency due to lymphomatoid granulomatosis in a 32-year-old man Lancet (IF 98.4) Pub Date : 2024-05-30 Ikki Sakuma MD PhD, Ryoichi Ishibashi MD PhD, Kosei Matsue MD PhD, Daniel F Vatner MD PhD, Yasuhiro Nakamura MD PhD, Prof Koutaro Yokote MD PhD, Prof Tomoaki Tanaka MD PhD
-
Eco-ethical care for people and the planet Lancet (IF 98.4) Pub Date : 2024-05-30 Kenneth Daniel Winkel, Amy Hahs, Sara Barron, Terry Hartig
-
We are failing to fulfil the definition of a doctor Lancet (IF 98.4) Pub Date : 2024-05-30 Hannah A Norman, Arpan R Mehta
-
Nigeria rolls out novel meningitis vaccine Lancet (IF 98.4) Pub Date : 2024-05-30 Patrick Ashinze, Nelson Mafua, Eniola Obafemi
-
Defensive scholarship: learning from academia's plagiarism crisis Lancet (IF 98.4) Pub Date : 2024-05-30 Nicholas Peoples
-
DEI infrastructures required for the best science and medicine Lancet (IF 98.4) Pub Date : 2024-05-30 Valerie A Tornini, Robert W Fernandez, Olivia V Goldman, Joanne Suarez
-
Opioids for back and neck pain: the OPAL trial – Authors' reply Lancet (IF 98.4) Pub Date : 2024-05-30 Caitlin M P Jones, Richard O Day, Bart W Koes, Jane Latimer, Chris G Maher, Andrew J McLachlan, Laurent Billot, Sana Shan, Chung-Wei Christine Lin, OPAL Investigators and Coordinators
-
Opioids for back and neck pain: the OPAL trial Lancet (IF 98.4) Pub Date : 2024-05-30 Nathan Beucler
-
Opioids for back and neck pain: the OPAL trial Lancet (IF 98.4) Pub Date : 2024-05-30 Yu Toda, Hiroto Ishiki, Naruaki Kawasaki, Sayaka Arakawa, Eriko Satomi
-
Opioids for back and neck pain: the OPAL trial Lancet (IF 98.4) Pub Date : 2024-05-30 Medhat Wahba, Pamela E Macintyre
-
Opioids for back and neck pain: the OPAL trial Lancet (IF 98.4) Pub Date : 2024-05-30 Asaf Weisman, James E Eubanks, Youssef Masharawi
-
Time to fast-track interventions to road traffic crises in Iran Lancet (IF 98.4) Pub Date : 2024-05-30 Homayoun Sadeghi-Bazargani, Alireza Razzaghi, Shahrzad Bazargan-Hejazi, Leila Doshmangir
-
Restrictive visa policies harm global scientific exchanges Lancet (IF 98.4) Pub Date : 2024-05-30 Alexander Smith, Albert Persaud, Dinesh Bhugra, Afzal Javed, Michael Liebrenz
-
Immunotherapeutics in nasopharyngeal carcinoma: a relentless CONTINUUM of success Lancet (IF 98.4) Pub Date : 2024-05-30 Nabil F Saba
-
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial Lancet (IF 98.4) Pub Date : 2024-05-30 Xu Liu MD, Yuan Zhang MD, Prof Kun-Yu Yang MD, Prof Ning Zhang MD, Prof Feng Jin MD, Prof Guo-Rong Zou MD, Prof Xiao-Dong Zhu MD, Prof Fang-Yun Xie MD, Xiao-Yu Liang MD, Wen-Fei Li MD, Prof Zhen-Yu He MD, Prof Nian-Yong Chen MD, Prof Wei-Han Hu MD, Hai-Jun Wu MD, Prof Mei Shi MD, Guan-Qun Zhou MD, Prof Yan-Ping Mao MD, Rui Guo MD, Rui Sun MD, Jing Huang MD, Shao-Qiang Liang MD, Wei-Li Wu MD, Zhen Su
Anti-PD-1 therapy and chemotherapy is a recommended first-line treatment for recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains unknown in patients with locoregionally advanced nasopharyngeal carcinoma. We assessed the addition of sintilimab, a PD-1 inhibitor, to standard chemoradiotherapy in this patient population. This multicentre, open-label, parallel-group
-
Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study Lancet (IF 98.4) Pub Date : 2024-05-29 Kenneth Chan MRCP, Elizabeth Wahome PhD, Apostolos Tsiachristas PhD, Alexios S Antonopoulos PhD, Parijat Patel BSc, Maria Lyasheva MPhil, Lucy Kingham BSc, Henry West DPhil, Evangelos K Oikonomou DPhil, Lucrezia Volpe BSc, Michail C Mavrogiannis MD, Edward Nicol FRCP, Tarun K Mittal FRCR, Thomas Halborg MSc, Rafail A Kotronias MRCP, David Adlam DPhil, Bhavik Modi PhD, Jonathan Rodrigues PhD, Nicholas
Coronary computed tomography angiography (CCTA) is the first line investigation for chest pain, and it is used to guide revascularisation. However, the widespread adoption of CCTA has revealed a large group of individuals without obstructive coronary artery disease (CAD), with unclear prognosis and management. Measurement of coronary inflammation from CCTA using the perivascular fat attenuation index
-
Blowing in the wind—India's health data and transparency issues Lancet (IF 98.4) Pub Date : 2024-05-29 Prajna Anirvan
-
A balanced perspective on India's health data and transparency Lancet (IF 98.4) Pub Date : 2024-05-29 Gururaj Arakeri, U S Vishal Rao